Associations Between Plasma Tenofovir Concentration and Renal Function Markers in HIV-infected Women

Overview

Journal South Afr J HIV Med

Specialty Infectious Diseases

Date 2018 Mar 24

PMID 29568614

Citations 3

Authors

Mwila Mulubwa

Malie Rheeders

Carla Fourie

Michelle Viljoen

Affiliations

Soon will be listed here.

Abstract

Background: Tenofovir disoproxil fumarate (TDF) has been associated with kidney tubular dysfunction and reduced renal function. Limited studies were performed in Europe and Asia that related plasma tenofovir (TFV) concentration with renal function; no such studies to date have been performed on Africans.

Objective: To investigate the correlation between plasma tenofovir (TFV) concentration and certain renal function markers in HIV-infected women on TDF antiretroviral therapy (ART). These markers were also compared to a HIV-uninfected control group.

Methods: HIV-infected women ( = 30) on TDF-based ART were matched with 30 controls for age and body mass index. Renal markers analysed were estimated glomerular filtration rate (eGFR), creatinine clearance (CrCl), serum creatinine, albuminuria, glucosuria, serum urea, serum uric acid, urine sodium and maximum tubular reabsorption of phosphate. Baseline eGFR and CrCl data were obtained retrospectively for the HIV-infected women. Plasma TFV was assayed using a validated HPLC-MS/MS method. Stepwise regression, Mann-Whitney test, unpaired and paired -tests were applied in the statistical analyses.

Results: TFV concentration was independently associated with albuminuria (adjusted = 0.339 = 0.001) in HIV-infected women. In the adjusted (weight) analysis, eGFR ( = 0.038), CrCl ( = 0.032) and albuminuria ( = 0.048) were significantly higher in HIV-infected compared to the uninfected women, but eGFR was abnormally high in HIV-infected women. Both eGFR ( < 0.001) and CrCl ( = 0.008) increased from baseline to follow-up in HIV-infected women.

Conclusion: Plasma TFV concentration was associated with increased albuminuria in HIV-infected women in this sub-study. Both eGFR and CrCl were increased in HIV-infected women from baseline. These findings should be confirmed in larger studies, and hyperfiltration in HIV-infected women warrants further investigation.

Citing Articles

Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy.

Mulubwa M, Viljoen M, Kruger I, Kruger H, Rheeders M South Afr J HIV Med. 2024; 18(1):739.

PMID: 39450052 PMC: 11500479. DOI: 10.4102/sajhivmed.v18i1.739.

Risk factors for impaired renal function in HIV-infected and HIV-uninfected adults: cross-sectional study in North-Western Tanzania.

Kavishe B, Kweka B, Nitsch D, PrayGod G, Jeremiah K, Faurholt-Jepsen D BMC Nephrol. 2021; 22(1):355.

PMID: 34715799 PMC: 8555220. DOI: 10.1186/s12882-021-02563-z.

Tenofovir-associated kidney disease in Africans: a systematic review.

Mtisi T, Ndhlovu C, Maponga C, Morse G AIDS Res Ther. 2019; 16(1):12.

PMID: 31171021 PMC: 6554992. DOI: 10.1186/s12981-019-0227-1.

References

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E . Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011; 6(7):e22661. PMC: 3143186. DOI: 10.1371/journal.pone.0022661. View

Rodriguez-Novoa S, Labarga P, DAvolio A, Barreiro P, Albalate M, Vispo E . Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010; 24(7):1064-6. DOI: 10.1097/QAD.0b013e32833202e2. View

Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K . Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011; 26(12):3923-9. DOI: 10.1093/ndt/gfr129. View

Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L . Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2009; 53(1):62-9. DOI: 10.1097/QAI.0b013e3181be6be2. View

Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S . Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2012; 62(4):375-80. DOI: 10.1097/QAI.0b013e31827ce4ee. View

OSeaghdha C, Hwang S, Upadhyay A, Meigs J, Fox C . Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis. 2010; 56(5):852-60. PMC: 3198053. DOI: 10.1053/j.ajkd.2010.04.013. View

Pushpakom S, Liptrott N, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M . Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011; 204(1):145-53. PMC: 3105036. DOI: 10.1093/infdis/jir215. View

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C . Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008; 197(1):102-8. DOI: 10.1086/524061. View

Ezinga M, Wetzels J, Bosch M, van der Ven A, Burger D . Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Antivir Ther. 2014; 19(8):765-71. DOI: 10.3851/IMP2761. View

10.

Kohler J, Hosseini S, Hoying-Brandt A, Green E, Johnson D, Russ R . Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009; 89(5):513-9. PMC: 2674517. DOI: 10.1038/labinvest.2009.14. View

11.

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J . Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009; 23(6):689-96. DOI: 10.1097/QAD.0b013e3283262a64. View

12.

Hall A . Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2012; 28(7):1011-23. DOI: 10.1007/s00467-012-2269-7. View

13.

Shinha T, Mi D, Liu Z, Orschell C, Lederman M, Gupta S . Relationships between renal parameters and serum and urine markers of inflammation in those with and without HIV infection. AIDS Res Hum Retroviruses. 2015; 31(4):375-83. PMC: 4378711. DOI: 10.1089/AID.2014.0234. View

14.

Deti E, Thiebaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D . Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2009; 11(5):308-17. DOI: 10.1111/j.1468-1293.2009.00780.x. View

15.

Helal I, Fick-Brosnahan G, Reed-Gitomer B, Schrier R . Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012; 8(5):293-300. DOI: 10.1038/nrneph.2012.19. View

16.

Ng D, Jacobson L, Brown T, Palella Jr F, Martinson J, Bolan R . HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection. AIDS. 2014; 28(3):377-86. PMC: 3972628. DOI: 10.1097/QAD.0000000000000094. View

17.

Levey A, Coresh J, Greene T, Marsh J, Stevens L, Kusek J . Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53(4):766-72. DOI: 10.1373/clinchem.2006.077180. View

18.

Teo K, Chow C, Vaz M, Rangarajan S, Yusuf S . The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009; 158(1):1-7.e1. DOI: 10.1016/j.ahj.2009.04.019. View

19.

Nauta F, Bakker S, van Oeveren W, Navis G, Homan van der Heide J, Goor H . Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis. 2011; 57(5):733-43. DOI: 10.1053/j.ajkd.2010.12.022. View

20.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View